微小RNA-1246在乳腺癌患者中的临床意义

doi:10.3969/j.issn.1673-8640.2017.07.007

检验医学 ›› 2017, Vol. 32 ›› Issue (7): 586-589.DOI: 10.3969/j.issn.1673-8640.2017.07.007

微小RNA-1246在乳腺癌患者中的临床意义

王攀, 朱杰, 顾婉红, 李招云

台州市中心医院检验科,浙江台州 318000

收稿日期:2016-03-14 出版日期:2017-08-08 发布日期:2017-08-09
作者简介:null
作者简介：王攀,女,1982年生,硕士,主管技师,主要从事分子免疫检验工作。
基金资助:
基金项目：浙江省科技计划项目（2012C37037）;台州市科技计划项目（2011ky0701）;台州市医学会科研项目（TZSYXH15-27）

MicroRNA-1246 in patients with breast cancer

WANG Pan, ZHU Jie, GU Wanhong, LI Zhaoyun

Department of Clinical Laboratory,Taizhou Central Hospital,Taizhou 318000,Zhejiang,China

Received:2016-03-14 Online:2017-08-08 Published:2017-08-09

摘要/Abstract

摘要：

目的分析微小RNA（miRNA）-1246在乳腺癌患者血清、组织中的表达,并探讨血清miRNA-1246对乳腺癌的诊断价值。方法采用荧光定量聚合酶链反应（PCR）检测100例乳腺癌患者、40名正常对照者血清以及30例乳腺癌组织、15例癌旁正常乳腺组织中miRNA-1246的表达。结果乳腺癌患者血清miRNA-1246相对表达量明显高于正常对照者（P<0.05）,组织miRNA-1246相对表达量与正常癌旁组织比较,差异无统计学意义（P>0.05）。血清miRNA-1246诊断乳腺癌的受试者工作特征（ROC）曲线下面积为0.904,敏感性和特异性分别为93%、75%。结论血清miRNA-1246诊断乳腺癌具有良好的敏感性和特异性,可以作为乳腺癌潜在的肿瘤生物标志物。

关键词: 微小RNA-1246, 乳腺癌, 体内外

Abstract:

Objective To analyze the expression of microRNA（miRNA）-1246 in sera and tissues among breast cancer patients,and to investigate the role of serum miRNA-1246 in the diagnosis of breast cancer. Methods Fluorescence quantitation polymerase chain reaction （PCR） was used to determine the expression of miRNA-1246 in sera of 100 breast cancer patients and 40 healthy controls,in 30 cases of breast cancer tissues and 15 cases of breast cancer adjacent tissues. Results The expression of miRNA-1246 was higher in sera of breast cancer patients than that in sera of healthy controls （P<0.05）. There was no statistical significance for miRNA-1246 expression between breast cancer tissues and breast cancer adjacent tissues （P>0.05）. Serum miRNA-1246 had an area under receiver operating characteristic（ROC） curve of 0.904,with sensitivity of 93% and specificity of 75%. Conclusions Serum miRNA-1246 shows good sensitivity and specificity for diagnosing breast cancer,and can be used as a potential tumor marker.

Key words: MicroRNA-1246, Breast cancer, In vitro and in vivo

中图分类号:

R446.1

王攀, 朱杰, 顾婉红, 李招云. 微小RNA-1246在乳腺癌患者中的临床意义[J]. 检验医学, 2017, 32(7): 586-589.

WANG Pan, ZHU Jie, GU Wanhong, LI Zhaoyun. MicroRNA-1246 in patients with breast cancer[J]. Laboratory Medicine, 2017, 32(7): 586-589.

图/表 2

参考文献 16

[1]	FERLAY J,SHIN H R,BRAY F,et al.Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008[J]. Int J Cancer,2010,127(12): 2893-2917.
[2]	郑莹,吴春晓,吴凡. 中国女性乳腺癌死亡现况和发展趋势[J]. 中华预防医学杂志,2011,45(2): 150-154.
[3]	WANG Y,XU C,WANG H,et al.Efficient derivation of human embryonic stem cell lines from discarded embryos through increases in the concentration of basic fibroblast growth factor[J]. Hum Cell ,2012,25(1): 16-23.
[4]	SCHEFFER A R,HOLDENRIEDER S,KRISTIANSEN G,et al.Circulating microRNAs in serum:novel biomarkers for patients with bladder cancer?[J]. World J Urol,2014,32(2):353-358.
[5]	WU D,ZHOU Y,PAN H,et al.MicroRNA-99a inhibiting cell proliferation,migration and invasion by targeting fibroblast growth factor receptor 3 in bladder cancer[J]. Oncol Lett,2014,7(4):1219-1224.
[6]	SODHI K K,BAHL C,SINGH N,et al.Functional genetic variants in pre-miR-146a and 196a2 genes are associated with risk of lung cancer in North Indians[J]. Future Oncol,2015,11(15):2159-2173.
[7]	EISSA S,MATBOLI M,SHARAWY A,et al.Prognostic and biological significance of microRNA-221 in breast cancer[J]. Gene,2015,574(1):163-167.
[8]	GOCZE K,GOMBOS K,JUHASZ K,et al.Unique microRNA expression profiles in cervical cancer[J]. Anticancer Res,2013,33(6):2561-2567.
[9]	MITCHELL P S,PARKIN R K,KROH E M,et al.Circulating microRNAs as stable blood-based markers for cancer detection[J]. Proc Natl Acad Sci U S A ,2008,105(30):10513-10518.
[10]	YANG Y,XIE Y J,XU Q,et al.Down-regulation of miR-1246 in cervical cancer tissues and its clinical significance[J]. Gynecol Oncol,2015,138(3):683-688.
[11]	JONES C I,ZABOLOTSKAYA M V,KING A J,et al.Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma[J]. Br J Cancer,2012,107(12): 1987-1996.
[12]	TAKESHITA N,HOSHINO I,MORI M,et al.Serum microRNA expression profile:miR-1246 as a novel diagnostic and prognostic biomarker for oesophageal squamous cell carcinoma[J]. Br J Cancer,2013,108(3):644-652.
[13]	IGUCHI H,KOSAKA N,OCHIYA T.Secretory microRNAs as a versatile communication tool[J]. Commun Integr Biol,2010,3(5): 478-481.
[14]	PIGATI L,YADDANAPUDI S C,IYENGAR R,et al.Selective release of microRNA species from normal and malignant mammary epithelial cells[J]. PLoS One,2010,5(10): e13515.
[15]	ZHANG Y,LIAO J M,ZENG S X,et al.P53 downregulates Down syndrome-associated DYRK1A through miR-1246[J]. EMBO Rep,2011,12(8):811-817.
[16]	LIAO J M,ZHOU X,ZHANG Y,et al.MiR-1246: a new link of the p53 family with cancer and Down syndrome[J]. Cell Cycle,2012,11(14):2624-2630.

微小RNA-1246在乳腺癌患者中的临床意义

MicroRNA-1246 in patients with breast cancer

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 2

参考文献 16

相关文章 15

编辑推荐

Metrics

[1]	王蓉, 邢连翔, 黄克亮, 李欣. miR-374靶向下调TRIM35表达可促进乳腺癌细胞增殖和侵袭[J]. 检验医学, 2023, 38(9): 812-817.
[2]	陈琛, 段奇, 陆佳团, 翟晓建, 王征, 张浩, 郭满. 三阴性乳腺癌患者ASH2L、HOXA2表达及其与淋巴转移的关系[J]. 检验医学, 2023, 38(6): 574-578.
[3]	张国良, 刘鷖雯, 何怡青, 许静, 杨翠霞, 高锋, 刘华. 乳腺癌患者血清HAS2、CD44水平变化及其临床意义[J]. 检验医学, 2023, 38(5): 424-429.
[4]	李牧, 龚东亮, 徐黎明, 彭荣. XPC rs2228000位点多态性与乳腺癌发病的关系[J]. 检验医学, 2023, 38(3): 235-239.
[5]	刘冲, 张静, 李胜, 赵奇. miR-335和Fra-1在乳腺癌中的表达及相互关系[J]. 检验医学, 2023, 38(2): 143-147.
[6]	高建朝, 王思思, 张志生, 张京力, 李晓霞, 马科, 冯志林, 周海丰, 王展海. miR-206、miR-125、miR-21在乳腺癌新辅助化疗疗效和预后评估中的价值[J]. 检验医学, 2023, 38(11): 1062-1068.
[7]	王晓烨, 冬国友, 刘志英. 乳腺癌组织中ZEB2、E-Cad表达与患者预后的关系[J]. 检验医学, 2022, 37(9): 815-820.
[8]	蔚芳芳, 赵琪, 杨丽萍, 王臣玉. 乳腺癌患者血液学参数与HER-2表达的关系[J]. 检验医学, 2022, 37(6): 514-517.
[9]	叶敬文, 沈云岳, 刘鷖雯, 何怡青, 杜艳, 张国良, 高锋, 杨翠霞. MAPK/ERK信号通路在逆转乳腺癌内分泌治疗耐药中的作用[J]. 检验医学, 2022, 37(4): 342-348.
[10]	张馨月, 陈亮, 郑宇. 血清C肽和胰岛素样生长因子结合蛋白3与乳腺癌患者死亡风险相关性分析[J]. 检验医学, 2022, 37(1): 36-40.
[11]	袁牧歌, 吴文坚, 胡朝晖, 陈嘉昌, 于世辉, 欧小华, 毛琳琳, 吴海艳. 靶向捕获高通量测序技术在检测早期乳腺癌胚系突变中的应用价值[J]. 检验医学, 2021, 36(3): 325-329.
[12]	刘秀芬, 敖洪峰, 敖金平. 程序化细胞死亡分子5在乳腺癌组织中的表达及其临床意义[J]. 检验医学, 2021, 36(11): 1151-1158.
[13]	金姝, 朱琪, 朱元, 袁亚, 蔡骁垚, 张骥, 闫佩毅. 乳腺癌组织及癌旁组织HER2基因CpG岛甲基化水平及其mRNA表达的研究[J]. 检验医学, 2020, 35(5): 481-486.
[14]	梅兆玲, 周文辉, 冯景. 外泌体在乳腺癌诊治中的研究进展[J]. 检验医学, 2020, 35(12): 1203-1206.
[15]	赵铮, 李毅, 杨飞翔. NKX2-5在乳腺癌患者他莫昔芬耐药中的作用及调控机制[J]. 检验医学, 2020, 35(1): 47-55.